Core Viewpoint - The company reported a slight increase in revenue for the six months ending June 30, 2025, driven by sales of its commercialized product, Envita® (a subcutaneous PD-L1 inhibitor) [1] Financial Performance - The company achieved revenue of 209 million RMB, representing a year-on-year increase of 1.33% from 206 million RMB in the same period of 2024 [1] - The loss attributable to shareholders was 89.35 million RMB, which is a reduction of 13.68% compared to the previous year [1] - The basic loss per share was 0.36 RMB [1] Sales and Growth Drivers - All revenue during the reporting period was generated from direct sales through distributors for the commercialized product Envita® [1] - The steady growth in sales revenue is attributed to the company's long-term commercial strategy and the enhanced capabilities of its commercialization team [1] - The increase in sales volume indicates potential for future growth [1]